Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 7/20 | 0.60 |
| ▸ | PPARA | Q07869 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | TACR1 | P25103 | 2/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4404718 | 1.00 | CASP1 (0.60) | CASP1PPARAPPARGTACR1CTSK | |
| SCHEMBL347303 | 0.89 | KYNU (0.59) | CASP1TACR1CTSKCTSLCTSB | |
| SCHEMBL1200462 | 0.89 | KYNU (0.59) | CASP1TACR1CTSKCTSLCTSB | |
| SCHEMBL345953 | 0.87 | PPARA (0.55) | CASP1PPARAPPARGTACR1CTSK | |
| SCHEMBL376886 | 0.87 | CASP1 (0.67) | CASP1PPARAPPARG | |
| SCHEMBL554032 | 0.87 | CASP1 (0.67) | CASP1PPARAPPARG | |
| SCHEMBL613386 | 0.87 | CASP1 (0.67) | CASP1PPARAPPARG | |
| SCHEMBL21409003 | 0.86 | PPARA (0.59) | CASP1PPARAPPARGTACR1CTSK | |
| SCHEMBL21409004 | 0.86 | PPARA (0.59) | CASP1PPARAPPARGTACR1CTSK | |
| SCHEMBL2912589 | 0.85 | CASP1 (0.60) | CASP1PPARAPPARGTACR1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI (FR) | 2014-03-13 | — | — | US | disclosed |
| US-8609681-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | CASP1 54/4885PPARA 1903/4885PPARG 3621/4885 |
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | CASP1 54/4885PPARA 1903/4885PPARG 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.